Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF T Lymphocytes.

Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA) refractory to other treatment options. However, many patients either do not respond or relapse after initially responding to these agents. This study was carried out to identify biomarkers that can distinguish responder from non-responder patients before the initiation of treatment.

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.

Objectives: To evaluate the efficacy of orally-administered alendronate compared with intravenously-administered zoledronate.

Methods: This prospective study was carried out at Barts Health HNS Trust between April 2010 and March 2012. This study compares changes in bone mineral density (BMD) in 234 patients treated with 2 bisphosphonates: alendronate taken orally, and zoledronate administered intravenously.

Bone loss in osteoporosis and arthritis. Pathogenesis and therapeutic strategies.

Bone makes up a framework that provides protection for internal body organs. The homeostasis of bone is maintained by balanced old bone resorption and new bone formation. However, this balance can be altered such as in postmenopausal women, patients with some cancers, and patients with chronic inflammatory conditions such as rheumatoid arthritis.